CANCER BASIC BIOLOGY (CBB) Cancer Basic Biology (CBB) is the sole fundamental science program in the Cancer Consortium. Its mission is three-fold: to conduct basic biological research related to cancer; to enable and conduct translational research that brings basic research findings to preclinical and clinical studies; and to train and mentor the next generation of cancer researchers. Scientifically, CBB research has three Specific Aims: (1) to elucidate the fundamental mechanisms that drive normal and cancer cell biology; (2) to use advanced genomics and epigenomics technologies to understand gene expression and phenotype in normal and cancer cells; and (3) to develop and apply new tools to facilitate basic science and cancer cell analyses. Each of these aims has a basic (discovery) and a translational (preclinical) component. The CBB Program leadership represents all three academic institutions and the breadth of fundamental research on cancer. Program Co-Leaders Jonathan Cooper and Ray Monnat take responsibility for cell biology and genomics/epigenomics, respectively. Associate Program Leaders David MacPherson and Barry Gumbiner add strength in animal models and cell/structural biology. All four CBB leaders are united in the goals of fostering research on the basic biology of normal and cancer cells and in promoting the development and application of new tools to improve cancer diagnosis and therapy. The program benefits the catchment area through research on lung, brain, and other cancer types that cause significant mortality and morbidity in our area. Our program structure and leadership work to foster high quality, cutting edge science within CBB and across Research Programs by providing opportunities to meet, share ideas, and develop new collaborative opportunities. We actively recruit new members with cancer- specific expertise, and identify new ways to promote both collaborative and translational science. CBB members play an additional key role in training the next generation of cancer scientists. The CBB Program currently has 105 members with 38 based at Fred Hutch, 63 based at University of Washington, and 4 based at Seattle Children?s. Since the prior cycle, CBB has gained a net of 32 members. The current research support of CBB members is $43.2M (direct costs), of which $27.3M is peer-reviewed funding, including $9M from the NCI. CBB Program members published a total of 1,057 papers over the current grant period, of which 12% were intra-programmatic, 16% were inter-programmatic, and 48% had external co-authors. Eleven of the 12 Consortium Shared Resources were utilized by CBB members in the course of their work. This P30 grant assists this program by providing administrative and logistical support for CBB meetings, pilot funding for new research projects, and recruitment resources for new faculty.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853659
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Kuzma, Jessica N; Cromer, Gail; Hagman, Derek K et al. (2018) Consuming glucose-sweetened, not fructose-sweetened, beverages increases fasting insulin in healthy humans. Eur J Clin Nutr :
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Puré, Ellen; Hingorani, Sunil R (2018) Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy. Trends Cancer 4:273-277
Yu, Hsiang; Cheng, Yu-Jen; Wang, Ching-Yun (2018) Methods for multivariate recurrent event data with measurement error and informative censoring. Biometrics 74:966-976
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005
Winters, Brian R; Vakar-Lopez, Funda; Brown, Lisha et al. (2018) Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 36:342.e7-342.e14
Molina, Yamile; Briant, Katherine J; Sanchez, Janeth I et al. (2018) Knowledge and social engagement change in intention to be screened for colorectal cancer. Ethn Health 23:461-479
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843

Showing the most recent 10 out of 1267 publications